Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226349 · ClinicalTrials.gov registry record · Phase 1
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 13
- Study locations
NCT07226349: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.
NCT07226349 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 105 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (45% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226349, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
Primary Outcome
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including physical examination findings, electrocardiogram results, laboratory values, and AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG BGB-43395
- DRUG BG-75098
Study Locations (13)
Texas
- The University of Texas Md Anderson Cancer Center - Houston
- Next Houston - Houston
Victoria
- Cabrini Hospital Malvern - Malvern East
- Peter Maccallum Cancer Centre - Melbourne
Hubei
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology - Wuhan
- Union Hospital Tongji Medical College Huazhong University of Science and Technologyjinyinhu Branch - Wuhan
Shandong
- Qilu Hospital of Shandong University - Jinan
- Weifang Peoples Hospital - Weifang
Alabama
- University of Alabama At Birmingham Hospital - Birmingham
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
Queensland
- Icon Cancer Centre Wesley - Auchenflower
Guangdong
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) - Guangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2029-03-15 |
| Phase | Phase 1 |
What NCT07226349 shows while recruiting
NCT07226349 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.
NCT07226349 lists 13 locations in 9 states (Texas, Victoria, Hubei).
Frequently Asked Questions
What is clinical trial NCT07226349 about?
NCT07226349 is a clinical study titled "A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors". The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
What is the current status of trial NCT07226349?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2025-12-11. Estimated completion is 2029-03-15.
What conditions does trial NCT07226349 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT07226349?
The interventions under investigation include: Fulvestrant (DRUG), BGB-43395 (DRUG), BG-75098 (DRUG).
Who is sponsoring clinical trial NCT07226349?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226349 being conducted?
This trial has 13 study locations across Alabama, Texas, New South Wales, Queensland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226349's enrollment target sits among peer trials
105 112th of 189 higher than 77 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI